The Coca-Cola Co K vs Vir Biotechnology Inc. Common Stock — how do they compare? The Coca-Cola Co K trades at $93.55 (market cap $394.89B), while Vir Biotechnology Inc. Common Stock trades at $10.41 (market cap $1.76B). The key difference: The Coca-Cola Co K is far larger — about 224.4× Vir Biotechnology Inc. Common Stock's market cap, and The Coca-Cola Co K pays a 2.31% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| KO | VIR | |
|---|---|---|
Market Cap | $394.89B | $1.76B |
Volume | 14,523,087 | 2,764,948 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $11.78 |
52-Week Low | $67.08 | $5.12 |
Typical Hold Time | 154 Days | 0 Days |
Enterprise Value | $422.06B | $1.32B |
Dividend Yield | 2.31% | — |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $90.11, up 0.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $0.97, beating estimates, and maintains robust profitability with a 28.56% net income margin. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook is positive, supported by consistent earnings beats, a high analyst buy rating (60.42%), and a $95.75 consensus price target. Risks include elevated valuation multiples and regional demand variability. The stock offers a reliable dividend, with a payout increase for 64 consecutive years.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →